Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000384752
Ethics application status
Approved
Date submitted
7/03/2013
Date registered
10/04/2013
Date last updated
10/04/2013
Type of registration
Retrospectively registered
Titles & IDs
Public title
Comparison between different doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile women undergoing IVF
Query!
Scientific title
Hormonal responses and clinical outcome following three doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile patients undergoing in vitro fertilization cycles
Query!
Secondary ID [1]
281896
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1139-2471
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Infertility
288296
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
288639
288639
0
0
Query!
Fertility including in vitro fertilisation
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Ovulatory patients undergoing in vitro fertilization cycles will start treatment with intramuscular injection of urinary gonadotropins, 2 ampoules (150 IU) per day and subcutaneous injections of GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. We administered human chorionic gonadotropin (hCG) when at least three follicles of 16 mm or more in diameter and adequate estradiol plasma concentrations were detected. Patients will be randomly assigned to three groups; group A, group B and group C . The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively.'
Query!
Intervention code [1]
286461
0
Treatment: Drugs
Query!
Comparator / control treatment
Patients will be randomly assigned to three groups; group A, group B and group C . The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively. Group A in which the patients will recieve the routine dose of 0.1 Triptorelin will be the control group.
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
288796
0
Pregnancy rate defined as the detection of rising B human chorionic gonadotropin titre in the serum and the ultrasound diagnosis of intruterine gestational sac.
Query!
Assessment method [1]
288796
0
Query!
Timepoint [1]
288796
0
within four weeks of intervention commencement
Query!
Secondary outcome [1]
301008
0
Occurence of LH surge by the measurement of LH level in the serum
Query!
Assessment method [1]
301008
0
Query!
Timepoint [1]
301008
0
Within two weeks of intervention commencement
Query!
Eligibility
Key inclusion criteria
Infertile patients undergoing in vitrofertilization cycles,
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
42
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients with ovarian failure
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The demographic data of the patients, hormonal levels, stimulation requirements and outcome variables will be compared for the three groups. Results will be presented as mean +/- standard deviation. Where appropriate, x2 test and t-test will be used for analysis using SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL USA). P<.05 was considered statistically significant.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/01/2012
Query!
Actual
1/01/2012
Query!
Date of last participant enrolment
Anticipated
1/06/2013
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
90
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
4840
0
Egypt
Query!
State/province [1]
4840
0
Query!
Funding & Sponsors
Funding source category [1]
286686
0
Self funded/Unfunded
Query!
Name [1]
286686
0
Query!
Address [1]
286686
0
Query!
Country [1]
286686
0
Egypt
Query!
Primary sponsor type
Other
Query!
Name
Sarhan IVF Cntre
Query!
Address
No 10 Alkawmya Street,
11144, Zagazig, Egypt
Query!
Country
Egypt
Query!
Secondary sponsor category [1]
285457
0
None
Query!
Name [1]
285457
0
Query!
Address [1]
285457
0
Query!
Country [1]
285457
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
288751
0
Zagazig University Fuculty of Medicine Ethical committee ZU-IRB
Query!
Ethics committee address [1]
288751
0
Zagazig Univeersity Faculty of Medicine 11118, Zagazig, Egypt
Query!
Ethics committee country [1]
288751
0
Egypt
Query!
Date submitted for ethics approval [1]
288751
0
10/05/2011
Query!
Approval date [1]
288751
0
15/07/2011
Query!
Ethics approval number [1]
288751
0
Query!
Summary
Brief summary
Gonadotropin releasing hormone agonist (GnRH-a) is used routinely in controlled ovarian stimulation for assisted reproduction either in its short (flare-up) or long protocol. The routine daily dose of the different agonists was introduced by trials and is not uniformly established. The objective of this prospective randomized controlled study was to characterize the daily changes in the levels of luteinizing hormone (LH) and estradiol (E2) and to compare the intracytoplasmic sperm injection (ICSI) outcome with 3 different doses of the GnRH-a used in a short protocol for normal ovulatory females. Patientswill be randomly assigned to three groups; group A (N=34), group B (N=34) and group C (N=23). All the patients will start treatment with urinary gonadotropins, 2 ampoules per day and GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
37634
0
Prof Abdulmagid Sarhan
Query!
Address
37634
0
Professor/ Abdulmagid Sarhan, Professor Zagazig University Borg Salma, Talaat Harb Street, 11014, Zagazig, Egypt
Query!
Country
37634
0
Egypt
Query!
Phone
37634
0
+201227972674
Query!
Fax
37634
0
Query!
Email
37634
0
[email protected]
Query!
Contact person for public queries
Name
37635
0
Abdulmagid Sarhan
Query!
Address
37635
0
Professor/ Abdulmagid Sarhan, Professor Zagazig University Borg Salma Talaat Harb Streat, 11014, Zagazig, Egypt
Query!
Country
37635
0
Egypt
Query!
Phone
37635
0
+201227972674
Query!
Fax
37635
0
Query!
Email
37635
0
[email protected]
Query!
Contact person for scientific queries
Name
37636
0
Professor/ Abdulmagid Sarhan
Query!
Address
37636
0
Professor/ Abdulmagid Sarhan, Professor Zagazig University Borg Salma Talaat Harb Street, 11014, Zagazig, Egypt
Query!
Country
37636
0
Egypt
Query!
Phone
37636
0
+201227972674
Query!
Fax
37636
0
Query!
Email
37636
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF